Court Rules In Favor Of IVAX In Summary Judgment Decision Regarding Sale Of Gabapentin.

MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that the Federal District Court in New Jersey granted a motion by IVAX for summary judgment of noninfringement of Pfizer's U.S. patent No 6,054,482 for Neurontin(R).

On August 18, 2004, IVAX commenced the initial commercialization of non-AB rated gabapentin tablets in 100 mg, 300 mg and 400 mg strengths. Gabapentin is the generic name of Neurontin(R), approved to treat seizures and postherapeutic neuralgia (PHN) and marketed by Warner-Lambert, a unit of Pfizer Inc. Neurontin(R) is sold by Warner-Lambert in five dosage strengths: 100 mg, 300 mg and 400 mg capsules, and 600 mg and 800 mg tablets. On March 23, 2005, IVAX commenced marketing AB-rated 100, 300 and 400 mg gabapentin capsules and on April 29, 2005, IVAX started marketing AB-rated 600 and 800 mg gabapentin tablets.

IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the Company's business and prospects, including the difficulty in predicting the timing and outcome of legal proceedings, including the outcome of any appeal of this decision regarding Pfizer's patent infringement claim against IVAX and others with respect to gabapentin; that the patent litigation with respect to these products could prevent us from selling these products, could result in substantial damages which could exceed the expected profit or selling price for these products; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Neurontin(R) is a registered trademark of Warner-Lambert Company, a unit of Pfizer Inc.

Copies of this and other news releases may be obtained free of charge from IVAX' website at http://www.ivax.com.